1. Home
  2. Directory
  3. Indiana
  4. Polis
  5. Emergency Medicine
  6. NPI Profile
  7. Prescriptions 1679506331

BRADLEY ESHELMAN MD
Prescription History 1679506331
Emergency Medicine in Indianapolis, IN


Quality Rating: 100 out of 100 score

NPI Status: Active since July 08, 2006

Contact Information

1500 N RITTER AVE
INDIANAPOLIS, IN
ZIP 46219
Phone: (317) 355-5041

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for BRADLEY ESHELMAN MD, an active Emergency Medicine specialist practicing in Indianapolis, IN. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 89 documented patient claims. Among these therapy options, the most frequently utilized medication is Methylprednisolone, which accounts for 27 claims alone.

Medication Index

A
C
D
M
O
No matching medications currently found on file.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 63
IN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills35.7
Peer Average Days Supply279
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.8% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $54.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.23

State Avg Cost Per Claim

$9.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Cephalexin

Generic Formulation: CephalexinSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 136
IN State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills36.4
Peer Average Days Supply393
Conservative Utilization

This provider writes prescriptions for this formulation 42.4% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $114.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.01

State Avg Cost Per Claim

$8.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 169
IN State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills32.2
Peer Average Days Supply431
Conservative Utilization

This provider writes prescriptions for this formulation 41.4% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $306.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.02

State Avg Cost Per Claim

$23.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Methylprednisolone

Generic Formulation: MethylprednisoloneSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 162
IN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills34.9
Peer Average Days Supply249
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $239.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.88

State Avg Cost Per Claim

$9.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A PREDNISOLONE derivative with similar anti-inflammatory action.

Therapeutic Applications

Methylprednisolone is used to treat conditions such as arthritis, blood disorders, severe allergic reactions, certain cancers, eye conditions, skin/kidney/intestinal/lung diseases, and immune system disorders. It decreases your immune system's response to various diseases to reduce symptoms such as swelling, pain, and allergic-type reactions. This medication is a corticosteroid hormone. Methylprednisolone may also be used with other medications in hormone disorders.

Ondansetron Odt

Generic Formulation: OndansetronSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 54
IN State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.7
Peer Average Days Supply287
Conservative Utilization

This provider writes prescriptions for this formulation 48.0% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $141.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.88

State Avg Cost Per Claim

$23.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like BRADLEY ESHELMAN MD provides transparency into local medical care patterns within Indianapolis, IN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Emergency Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.